This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
by Zacks Equity Research
Axsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi (solriamfetol) for treating major depressive disorder. The stock rises 6%.
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
by Zacks Equity Research
Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 39.67% and 1.64%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Intra-Cellular Therapies (ITCI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Axsome (AXSM) Might Surprise This Earnings Season
by Zacks Equity Research
Axsome (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Axsome (AXSM) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Axsome (AXSM) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also provides regulatory updates on its pipeline candidates. Shares rise.
Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?
by Zacks Equity Research
Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Acadia's (ACAD) Nuplazid Sales Drive Growth Amid Competition
by Zacks Equity Research
Acadia (ACAD) is witnessing robust growth in revenues, driven by Nuplazid and Daybue sales. However, dependence on Nuplazid sales for revenues, along with stiff competition, remains a woe.
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Axsome (AXSM) incurs a wider-than-expected loss in the third quarter of 2023 while sales beat estimates. The company's shares declined post earnings announcement.
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
by Zacks Equity Research
Nektar (NKTR) incurs a narrower-than-expected second-quarter loss but misses on revenues.
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in the second quarter. The company provides updates on its central nervous system candidates.
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 19.35% and 16.21%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q2 Earnings Beat, Nerlynx Sales Outperform
by Zacks Equity Research
Puma Biotechnology (PBYI) beats second-quarter earnings and sales estimates. Stock rises in after-hours.
4 Biotech Stocks Set to Outpace Q2 Earnings Estimates
by Sundeep Ganoria
Let us look at some biotech stocks, ARCT, AXSM, EBS and NVAX, which are poised to beat on second-quarter earnings.
Zoetis (ZTS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) companion animal and livestock products are expected to have driven sales in second-quarter 2023, partially offset by lower sales of swine products.
ANI Pharmaceuticals (ANIP) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
ANI Pharmaceuticals' (ANIP) second-quarter 2023 performance is likely to have been driven by rising generic and rare disease product revenues.
Adaptimmune (ADAP) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Adaptimmune (ADAP) is expected to provide regulatory and developmental updates on its pipeline programs in its upcoming earnings release, given the absence of marketed products in its portfolio.